参附注射液联合卡培他滨、奥沙利铂治疗胃癌的疗效观察

目的观察参附注射液在晚期胃癌联合卡培他滨和奥沙利铂（XELOX）化疗方案中的作用。方法将135例胃癌患者随机分为观察组和对照组，观察组67例患者同时予参附注射液加XELOX方案化疗；对照组68例予单纯XELOX方案化疗。每3周重复1次，化疗3个疗程后评价不良反应和生活质量。结果观察组有效率44．8％（30／67），对照组有效率47．1％（32／68），两组比较差异无显著性（P=0．790）；不良反应（包括贫血和恶心呕吐）观察组明显少于对照组（P〈0．05）；KPS评分改善率分别是49．3％和32．3％（P=0．046）。结论参附注射液联合XELOX方案治疗晚期胃癌，可明显减轻化疗药物所产生的贫血和恶心呕吐不良反应，提高患者生活质量。

Comparative study on treatment of advanced gastric carcinoma by shenfu injection combined with XELOX Regimen

Objective To evaluate the therapeutic efficacy and adverse reaction of shenfu injection combined with XELOX regimen for treatment of patients with advanced gastric cancer, and controlled with those of XELOX regimen alone. Meth- ods All 135 patients were randomized into two groups,and all received XELOX regimen. To the treatment group （67 pa- tients） ,shenfu injection was administered additionally, while to the control group（68 patients）. The regimen was given ev- ery 3 weeks,and all enrolled patients were evaluated for adverse reaction after 3 cycles of treatment. Results The response rate in the treatment group was 44.8%（30/67）,and in the control group was 47.1%（32/68）. The difference of response rates between the two groups was no statistically significant（P = 0.790）,but the adverse reaction, which included anemia, nausea and vomiting,presented in the treatment group was greatly less than that in the control group （P 〈 0.05）. The KPS score improving rate in the two groups was 49.3% and,32.3% respectively （P = 0.046）. Conclusion Shenfu injection in combining with XELOX regimen can evidently reduce the adverse reaction of chemotherapy in treating advanced gastric cancer and could also improve the quality of life.